

Erratum

SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer

J-L Boulay, G Mild, A Lowy, J Reuter, M Lagrange, L Terracciano, U Laffer, R Herrmann and C Rochlitz

British Journal of Cancer (2003) **89**, 422. doi:10.1038/sj.bjc.6601020 www.bjcancer.com
© 2003 Cancer Research UK

Correction to: British Journal of Cancer (2002) **87**, 630–634. doi:10.1038/sj.bjc. 6600511

Unfortunately due to a typesetting error, Figure 2 was reproduced incorrectly.

The correct version is reprinted below:




Figure 2 Disease-free survival by 5-FU treatment (SMAD4 deleted).

The publisher would like to apologise for any inconvenience this may have caused.